MCID: PPL007
MIFTS: 43

Papillary Serous Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Papillary Serous Adenocarcinoma

MalaCards integrated aliases for Papillary Serous Adenocarcinoma:

Name: Papillary Serous Adenocarcinoma 12 15
Serous Surface Papillary Carcinoma 12 73
Papillary Serous Cystadenocarcinoma 73
Micropapillary Serous Carcinoma 12
Papillary Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2632
SNOMED-CT 68 15674004 90282004

Summaries for Papillary Serous Adenocarcinoma

Disease Ontology : 12 A papillary adenocarcinoma that derives from epithelial cells originating in glandular tissue, which form complex papillary structures with psammoma bodies.

MalaCards based summary : Papillary Serous Adenocarcinoma, also known as serous surface papillary carcinoma, is related to primary peritoneal carcinoma and uterine corpus serous adenocarcinoma. An important gene associated with Papillary Serous Adenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Hepatitis C and Hepatocellular Carcinoma and Integrated Cancer Pathway. The drugs Cisplatin and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include ovary, uterus and bone, and related phenotypes are cellular and homeostasis/metabolism

Related Diseases for Papillary Serous Adenocarcinoma

Diseases related to Papillary Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
# Related Disease Score Top Affiliating Genes
1 primary peritoneal carcinoma 32.1 BRCA1 PGR TP53
2 uterine corpus serous adenocarcinoma 32.1 BRCA1 TP53
3 malignant mixed mullerian tumor 30.7 KRT7 PGR
4 bilateral breast cancer 30.0 BRCA1 PGR
5 papillary carcinoma 29.6 KRT20 KRT7 NKX2-1 PGR
6 ovarian cancer 27.7 BRCA1 KRT7 PGR TP53
7 ovary papillary carcinoma 11.3
8 cribriform carcinoma 10.6 KRT7 PGR
9 oncocytic breast carcinoma 10.6 KRT7 PGR
10 benign metastasizing leiomyoma 10.6 KRT7 PGR
11 adenoid basal cell carcinoma 10.6 KRT7 PGR
12 apocrine adenocarcinoma 10.6 KRT7 PGR
13 pancreatic serous cystadenoma 10.6 KRT7 PGR
14 solid adenocarcinoma with mucin production 10.6 KRT7 NKX2-1
15 corneal abscess 10.6 KRT7 PGR
16 adenocarcinoma 10.6
17 ovarian germ cell teratoma 10.6 KRT7 NKX2-1
18 ovarian germ cell cancer 10.6 KRT7 NKX2-1
19 papillary adenoma 10.6 KRT7 NKX2-1
20 sertoli-leydig cell tumor 10.6 KRT7 PGR
21 bronchiolo-alveolar adenocarcinoma 10.6 KRT7 NKX2-1
22 intestinal perforation 10.5 KRT7 NKX2-1
23 vaginal benign neoplasm 10.5 KRT20 KRT7
24 anus basaloid carcinoma 10.5 KRT7 PTGER4
25 seminal vesicle adenocarcinoma 10.5 KRT20 KRT7
26 pulmonary sclerosing hemangioma 10.5 KRT7 NKX2-1
27 transverse colon cancer 10.5 KRT20 KRT7
28 appendix adenocarcinoma 10.5 KRT20 KRT7
29 ovarian large-cell neuroendocrine carcinoma 10.5 KRT20 KRT7
30 vaginal adenoma 10.5 KRT20 KRT7
31 vaginal tubulovillous adenoma 10.5 KRT20 KRT7
32 eyelid neoplasm 10.5 KRT20 KRT7
33 glandular cystitis 10.5 KRT20 KRT7
34 krukenberg carcinoma 10.5 KRT20 KRT7
35 large intestine adenocarcinoma 10.5 KRT20 KRT7
36 linitis plastica 10.5 KRT20 KRT7
37 breast secretory carcinoma 10.5 KRT7 PGR
38 adenoid squamous cell carcinoma 10.5 KRT20 KRT7
39 large cell acanthoma 10.5 KRT7 PTGER4
40 nodular hidradenoma 10.5 KRT7 PTGER4
41 vulval paget's disease 10.5 KRT20 KRT7
42 bile duct cystadenocarcinoma 10.5 KRT20 KRT7
43 atypical choroid plexus papilloma 10.5 KRT7 NKX2-1
44 intratubular embryonal carcinoma 10.5 KRT20 KRT7
45 ovarian mucinous adenocarcinoma 10.5 KRT20 KRT7
46 gastric diffuse adenocarcinoma 10.5 KRT20 KRT7
47 sclerosing hemangioma 10.5 KRT7 NKX2-1
48 meibomian cyst 10.5 KRT20 KRT7
49 bladder lymphoma 10.5 KRT20 KRT7
50 bladder adenocarcinoma 10.5 KRT20 KRT7

Graphical network of the top 20 diseases related to Papillary Serous Adenocarcinoma:



Diseases related to Papillary Serous Adenocarcinoma

Symptoms & Phenotypes for Papillary Serous Adenocarcinoma

MGI Mouse Phenotypes related to Papillary Serous Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.87 BRCA1 KRT7 NKX2-1 PGR PTGER4 STK36
2 homeostasis/metabolism MP:0005376 9.8 TP53 BRCA1 KRT7 NKX2-1 PGR PTGER4
3 neoplasm MP:0002006 9.55 BRCA1 NKX2-1 PGR PTGER4 TP53
4 respiratory system MP:0005388 9.35 TP53 BRCA1 NKX2-1 PTGER4 STK36
5 skeleton MP:0005390 9.1 TP53 BRCA1 NKX2-1 PGR PTGER4 STK36

Drugs & Therapeutics for Papillary Serous Adenocarcinoma

Drugs for Papillary Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
2
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
3
Epirubicin Approved Phase 3 56420-45-2 41867
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
6
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
7
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
8
Letrozole Approved, Investigational Phase 2, Phase 3,Phase 3 112809-51-5 3902
9
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
10
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
11
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
12
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
13
Doxil Approved June 1999 Phase 3,Phase 2 31703
14 Hormones Phase 2, Phase 3,Phase 3
15 Antimitotic Agents Phase 2, Phase 3,Phase 1
16 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
17 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
18 Topoisomerase Inhibitors Phase 3,Phase 2
19 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
20 Antifungal Agents Phase 2, Phase 3,Phase 1
21 Anti-Infective Agents Phase 2, Phase 3,Phase 1
22 Hormone Antagonists Phase 2, Phase 3,Phase 3
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 3
24 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
25 Antineoplastic Agents, Hormonal Phase 2, Phase 3
26 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
27 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
28 Aromatase Inhibitors Phase 2, Phase 3,Phase 3
29 Estrogen Antagonists Phase 2, Phase 3,Phase 3
30 Estrogens Phase 2, Phase 3,Phase 3
31 Steroid Synthesis Inhibitors Phase 2, Phase 3,Phase 3
32 Anticoagulants Phase 2, Phase 3
33 Bone Density Conservation Agents Phase 2, Phase 3
34 Calcium, Dietary Phase 2, Phase 3
35 Chelating Agents Phase 2, Phase 3
36 Estrogen Receptor Modulators Phase 2, Phase 3
37 Selective Estrogen Receptor Modulators Phase 2, Phase 3
38 topoisomerase I inhibitors Phase 2, Phase 3
39 Citrate Nutraceutical Phase 2, Phase 3
40
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
41
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
42
Cimetidine Approved, Investigational Phase 2 51481-61-9 2756
43
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
44
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
45
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
46
Promethazine Approved, Investigational Phase 2 60-87-7 4927
47
Ifosfamide Approved Phase 2 3778-73-2 3690
48
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
49
Mesna Approved, Investigational Phase 2 3375-50-6 598
50
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
3 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
4 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
5 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
6 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
7 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
8 Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Unknown status NCT00003560 Phase 2 carboplatin;docetaxel
9 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
10 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
11 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
12 Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Completed NCT00022620 Phase 2 paclitaxel
13 Uterine Papillary Serous Cancer (UPSC) Trial Completed NCT00147680 Phase 2 Paclitaxel, Carboplatin
14 A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus Completed NCT00231842 Phase 2 Ifosfamide
15 Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer Completed NCT00052312 Phase 2 cisplatin;doxorubicin hydrochloride;paclitaxel
16 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
17 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
18 Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer Completed NCT00664781 Phase 2 rucaparib (CO-338; formally AG-014699 or PF-01367338)
19 Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Active, not recruiting NCT00416455 Phase 1, Phase 2 ferumoxtran-10
20 Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma Terminated NCT00653328 Phase 2 atrasentan hydrochloride;doxil
21 A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers Terminated NCT00231829 Phase 2 Celecoxib
22 Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors Completed NCT01198184 Phase 1 temsirolimus;gamma-secretase/Notch signalling pathway inhibitor RO4929097
23 Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Withdrawn NCT02050009 Phase 1 metformin hydrochloride;carboplatin;paclitaxel
24 Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer Unknown status NCT01150682
25 Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer Completed NCT01096394
26 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704
27 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169
28 Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer Not yet recruiting NCT01344837
29 Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine Not yet recruiting NCT02774395

Search NIH Clinical Center for Papillary Serous Adenocarcinoma

Genetic Tests for Papillary Serous Adenocarcinoma

Anatomical Context for Papillary Serous Adenocarcinoma

MalaCards organs/tissues related to Papillary Serous Adenocarcinoma:

41
Ovary, Uterus, Bone, Liver, Lymph Node, Cervix, Brain

Publications for Papillary Serous Adenocarcinoma

Articles related to Papillary Serous Adenocarcinoma:

(show all 37)
# Title Authors Year
1
Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review. ( 28399919 )
2017
2
Filarial worm residing in ovarian papillary serous adenocarcinoma-A rare case report. ( 27444355 )
2016
3
Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. ( 23290009 )
2013
4
Multiple brain metastases in a patient with uterine papillary serous adenocarcinoma: Treatment options for this rarely seen metastatic brain tumor. ( 24032086 )
2013
5
Malignant mixed mullerian tumor of endometrium coexisting with bilateral papillary serous adenocarcinoma of fallopian tube: a rare case report. ( 24293882 )
2012
6
Papillary-serous adenocarcinoma of the uterine cervix during tamoxifen therapy after bilateral breast cancer. ( 23155282 )
2012
7
F-18 fluoride uptake in calcified extraosseous metastases from ovarian papillary serous adenocarcinoma. ( 22157054 )
2012
8
Papillary serous adenocarcinoma of the uterine cervix: a case report. ( 21614930 )
2011
9
Acute gastric outlet obstruction secondary to papillary serous adenocarcinoma of the endometrium with peritoneal psammomatous implants: a case report. ( 19132421 )
2010
10
Successful Treatment of Primary Vaginal Papillary Serous Adenocarcinoma Using Chemoradiation Followed by Brachytherapy. ( 20740170 )
2009
11
99mTc-MDP and 18F-FDG uptake in calcified metastatic lesions from ovarian papillary serous adenocarcinoma. ( 19936349 )
2009
12
Malignant pericardial tamponade secondary to papillary serous adenocarcinoma of the ovary. ( 17491236 )
2007
13
Pulmonary papillary serous adenocarcinoma with intraperitoneal and ovarian tumors: identification of primary site. A case report. ( 16515596 )
2006
14
Establishment and characterization of a cell line derived from a human serous surface papillary carcinoma of the ovary. ( 17257376 )
2006
15
A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report. ( 16930493 )
2006
16
Serous surface papillary carcinoma of the peritoneum: clinical, radiologic, and pathologic findings in 11 patients. ( 15385282 )
2004
17
Establishment and characterization of two cell lines (HEC-155, HEC-180) derived from uterine papillary serous adenocarcinoma. ( 15285295 )
2004
18
Papillary serous adenocarcinoma of the endometrium: CT-pathologic correlation. ( 15150003 )
2004
19
CT features of serous surface papillary carcinoma of the ovary. ( 15547217 )
2004
20
Weekly topotecan in a heavily pretreated patient with peritoneal papillary serous adenocarcinoma. ( 15228430 )
2004
21
Papillary serous adenocarcinoma of the ovary diagnosed after malignant pericardial tamponade and embolic stroke. ( 11855887 )
2002
22
Cerebellar metastasis from papillary serous adenocarcinoma of the ovary mimicking MAcniA"re's disease. A case report. ( 11304872 )
2001
23
Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? ( 11104623 )
2000
24
Papillary serous adenocarcinoma of the endocervix: A rare neoplasm. Immunohistochemical profile. ( 11240696 )
2000
25
The combination paclitaxel, carboplatin and megestrol acetate is effective in women with recurrent uterine papillary serous adenocarcinoma. ( 10422674 )
1999
26
Supradiaphragmatic manifestations of papillary serous adenocarcinoma of the ovary. ( 10580766 )
1999
27
Multiple nodular metastases in mesenteric panniculitis by uterine papillary serous adenocarcinoma (UPSC): CT appearance of a case. ( 10416083 )
1999
28
Cytologic features of papillary serous adenocarcinoma of the uterine cervix. ( 9126137 )
1997
29
Varieties of serous surface papillary carcinoma of the peritoneum in northern Germany: a thirty-year autopsy study. ( 8598333 )
1995
30
Histologic characterization of uterine papillary serous adenocarcinoma. ( 7705679 )
1995
31
Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. ( 7915964 )
1994
32
Papillary serous adenocarcinoma of the endometrium: a clinicopathologic study of 19 cases. ( 1634141 )
1992
33
Papillary serous adenocarcinoma of the uterine cervix: a report of three cases. ( 1495949 )
1992
34
Invasive papillary serous adenocarcinoma of the endocervix in pregnancy; a case report. ( 1855609 )
1991
35
Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects. ( 2013445 )
1991
36
Papillary serous adenocarcinoma of the endometrium. ( 3960439 )
1986
37
Papillary serous adenocarcinoma. ( 18870241 )
1948

Variations for Papillary Serous Adenocarcinoma

Expression for Papillary Serous Adenocarcinoma

Search GEO for disease gene expression data for Papillary Serous Adenocarcinoma.

Pathways for Papillary Serous Adenocarcinoma

Pathways related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.11 BRCA1 TP53
2 11.03 BRCA1 TP53
3 10.97 BRCA1 TP53
4 10.76 BRCA1 TP53
5 10.65 BRCA1 TP53
6 10.42 BRCA1 TP53
7 9.9 BRCA1 TP53

GO Terms for Papillary Serous Adenocarcinoma

Biological processes related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell cycle arrest GO:0071158 8.96 BRCA1 TP53
2 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.62 BRCA1 TP53

Molecular functions related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.13 BRCA1 NKX2-1 TP53
2 enzyme binding GO:0019899 8.92 BRCA1 NKX2-1 PGR TP53

Sources for Papillary Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....